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Aim To determine the diagnostic accuracy of the combination of quantitative 
capnometry (QC), N-terminal pro-brain natriuretic peptide (NT-proBNP), and 
clinical assessment in differentiating heart failure (HF)-related acute dyspnea 
from pulmonary-related acute dyspnea in a pre-hospital setting.
Methods This prospective study was performed in the Center for Emergency 
Medicine Maribor, Slovenia, January 2005 – June 2007. Two groups of patients 
with acute dyspnea apnea were compared: HF-related acute dyspnea group 
(n = 238) vs pulmonary-related acute dyspnea (asthma/COPD) group (n = 203). 
The primary outcome was the comparison of combination of QC, NT-proBNP, 
and clinical assessment vs NT-proBNP alone or NT-proBNP in combination with 
clinical assessment, in differentiating HF-related acute dyspnea from pulmo-
nary-related acute dyspnea (asthma/COPD) in pre-hospital emergency setting, 
using the area under the receiver operating characteristic curve (AUROC). The 
secondary outcomes end points were identification of independent predictors 
for final diagnosis of acute dyspnea (caused by acute HF or pulmonary diseas-
es), and determination of NT-proBNP levels, as well as capnometry, in the sub-
group of patients with a previous history of HF and in the subgroup of patients 
with a previous history of pulmonary disease.
Results In differentiating between cardiac and respiratory causes of acute dys-
pnea in pre-hospital emergency setting, NT-proBNP in combination with PetCO2 
and clinical assessment (AUROC, 0.97; 95% confidence interval [CI], 0.90-0.99) 
was superior to combination of NT-proBNP and clinical assessment (AUROC, 
0.94; 95% CI, 0.88-0.96; P = 0.006) or NT-proBNP alone (AUROC, 0.90; 95% CI, 0.85-
0.94; P = 0.005). The values of NT-proBNP≥2000 pg/mL and PetCO2 ≤ 4 kPa were 
strong independent predictors for acute HF. In the group of acute HF dyspne-
ic patients, subgroup of patients with previous COPD/asthma had significantly 
higher PetCO2 (3.8 ± 1.2 vs 5.8 ± 1.3 kPa, P = 0.009). In the group of COPD/asthma 
dyspneic patients, NT-proBNP was significantly higher in the subgroup of pa-
tients with previous HF (1453.3 ± 552.3 vs 741.5 ± 435.5 pg/mL, P = 0.010).
Conclusion In differentiating between cardiac and respiratory causes of acute 
dyspnea in pre-hospital emergency setting, NT-proBNP in combination with 
capnometry and clinical assessment was superior to NT-proBNP alone or NT-
proBNP in combination with clinical assessment.
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In patients presenting with acute dyspnea in pre-hospital 
setting, the early and correct diagnosis may present a sig-
nificant clinical challenge (1,2). Physical examination, chest 
radiography, electrocardiography, and standard biological 
tests often fail to accurately differentiate heart failure (HF) 
from pulmonary causes of dyspnea (3). Timely differentia-
tion of HF from other causes of dyspnea may permit the 
early institution of appropriate medical therapy (4-6). Brain 
natriuretic peptide (BNP) and amino-terminal pro-brain na-
triuretic peptide (NT-proBNP) have been proposed as early 
markers of HF and demonstrated to be useful for diagnos-
ing and excluding HF in emergency department (7-9). A 
combination of BNP or NT-proBNP testing and standard 
clinical assessment has been suggested to be superior to 
either tool used in isolation (7,8,10). Some previous stud-
ies have also suggested that quantitative capnometry (QC) 
may be useful in differentiating between cardiac and ob-
structive causes of respiratory distress (11,12). Therefore, 
we hypothesized that a new combination of NT-proBNP 
testing, standard clinical assessment, and partial pressure 
of end-tidal CO2 (PetCO2) would optimize evaluation and 
differentiation of acute dyspnea in a pre-hospital setting.
The aim of this study was to determine the accuracy of 
combination of QC, NT-proBNP, and clinical assessment in 
differentiating acute HF from obstructive pulmonary dis-
ease (COPD/asthma) as a cause of acute dyspnea in pre-
hospital emergency setting.
SubjectS and MethodS
Study design and setting
This prospective cohort study was performed in the pre-
hospital emergency setting (Center for Emergency Medi-
cine Maribor, Slovenia, Europe) between January 2005 and 
June 2007. The study was approved by the Ethical Review 
Board of the Ministry of Health of Slovenia.
Patients
During the period of the study, 546 consecutive patients 
with acute dyspnea were treated by emergency teams 
(emergency physician, register nurse, and medical techni-
cian/driver in an ambulance-car or at pre-hospital emer-
gency medical center). After pre-hospital care, all patients 
were admitted to the University Clinical Center Maribor 
and followed until discharge.
To be eligible for the study, a patient had to present 
with shortness of breath as the primary complaint 
(defined as either the sudden onset of dyspnea without 
history of chronic dyspnea or an increase in the severity 
of chronic dyspnea). Exclusion criteria were age <18 years, 
history of renal insufficiency, trauma, severe coronary 
ischemia (unless patient’s predominant presentation was 
dyspnea), and other causes of dyspnea: pneumonia, pul-
monary embolism, carcinoma, pneumothorax, pleural ef-
fusion, intoxications (drugs), anaphylactic reactions, upper 
airway obstruction, bronchial stenosis, and gastroesopha-
geal reflux disorder, according to the history, clinical sta-
tus, and additional laboratory tests available in pre-hospital 
setting (D-dimer, troponin, C-reactive protein).
There were 441 patients who met the criteria for inclusion 
in the survey. Hundred and five patients were excluded 
from the study. Recruitment, exclusion, and subsequent 
grouping of all patients are shown in the flowchart (Fig-
ure 1).
data collection
After enrollment, patient’s demographic characteristics, 
symptoms and signs, medical history, medication use, 
chest X-ray, and standard blood test results (after admis-
sion to the hospital) were recorded.
Our protocol for clinical assessment of HF-related acute 
dyspnea (the pre-hospital clinical assessment for HF) was 
designed based on Boston (13) and Framingham criteria 
for HF (14) (Table 1). We did not use certain criteria from the 
original protocols, which were not available in the prehos-
pital setting (eg, chest radiography).
For additional evaluation of patients with suspect obstruc-
tive causes of dyspnea, we included criteria for clinical as-
sessment of severe asthma (diffuse polyphonic bilateral 
and particular expiratory wheezes, chest tightness, short-
ness of breath, using accessory muscles of breathing, signs 
of hyperinflation, atopic condition, personal or family his-
tory of asthma, tachypnea, previous asthma and asthma 
medications, and the value of modified Boston criteria for 
HF≤5) (15,16) and criteria for chronic obstructive pulmo-
nary disease (COPD) exacerbation (history of COPD, COPD 
medications, cough, worsening dyspnea, increased spu-
tum production and volume, increased sputum purulence, 
rhonchi and rales, modified Boston criteria for HF≤5) (17).
The final hospital diagnosis of HF-related acute dyspnea 
and pulmonary-related acute dyspnea (the hospital ref-
erence standard for HF and pulmonary diseases: asthma/
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COPD) was confirmed by cardiologist and/or intensive 
care physician in the University Clinical Center Maribor, us-
ing the reference standard definition for HF and pulmo-
nary diseases in accordance with previously cited instru-
ments (13-19), including chest X-ray, echocardiographic 
examination, cardiac functional assessment (exercise test), 
pulmonary function test, full blood count, biochemistry, 
and invasive investigation or angiography (17).
According to these criteria, identification of independent 
predictors for final diagnosis of acute dyspnea (caused 
by acute HF or pulmonary diseases) was performed by 
examination of 26 variables (Table 2): age, sex, nocturnal 
dyspnea, orthopnea, cough, sputum production, fever, 
murmur, lung rales, wheezes, pulse rate, jugular venous 
distension, lower extremity edema, ECG, history of COPD/
asthma medications or HF medications, troponin T, PetCO2, 
Sao2, NT-proBNP, the need for endotracheal intubation, pre-
vious arrhythmia, history of previous, acute myocardial in-
farction (AMI), congestive heart failure (CHF), or COPD, and 
the value of modified Boston criteria for HF. Central venous 
pressure (CVP) in the field was assessed by the visualiza-
tion of external jugular vein. This correlates well with cath-
eter-measured CVP (18) and may give a reliable estimate of 
CVP, categorized as low (<5 cm H2O) or high (≥10 cm H2O) 
when the top of the external jugular veins is >3 cm of verti-
cal distance above the sternal angle.
Two groups of patients (HF-related acute dyspnea group 
and pulmonary-related acute dyspnea [asthma/COPD] 
group) were further divided according to previous his-
tory of HF or COPD/asthma (acute HF dyspneic patients 
with previous history of HF, acute HF dyspneic patients 
with previous history of COPD/asthma, acute COPD/asth-
ma dyspneic patients with previous history of HF, acute 
COPD/asthma dyspneic patients with previous history of 
COPD/asthma) for determination of NT-proBNP levels, 
as well as for capnometry.
Figure 1.
the flow diagram of recruitment, exclusion, and subsequent grouping of all patients in the study.
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Measurements
NT-proBNP. During initial evaluation (before application 
of medicines), a 5-mL sample of blood was collected into 
a tube containing calcium disodium edetate for blinded 
measurement of NT-proBNP. The level of NT-proBNP was 
measured using a Cardiac Reader (Roche Diagnostics, 
Mannheim, Germany) and recorded in the special proto-
col. The test was finished within 15 minutes.
PetCO2. PetCO2 was obtained by Lifepak 12 (Medtronic 
Physiocontrol, Corporate Headquarters, Redmond, WA, 
USA); an average PetCO2 value of the first three measure-
ments in the first minute after endotracheal intubation or 
nasal measurement was registered.
blinding (masking) of physicians
The raters who made the diagnosis (in pre-hospital set-
ting – pre-hospital emergency physicians, at admission 
to hospital – internists at emergency department, and 
at discharge from the hospital with the final diagno-
sis – cardiologists or/and intensive care physicians) 
were blinded to the results of NT-pro-BNP. In addition, the 
investigators of NT-proBNP did not collaborate in making 
the final diagnosis.
On the other hand, pre-hospital emergency physicians 
were not blinded to the value of PetCO2 because QC 
represents the routine method in Slovenian pre-hospital 
emergency medicine. To avoid bias, the value of PetCO2 
was recorded by the emergency physician in the field but 
did not affect the diagnosis. The raters who made the di-
agnosis in the hospital were blinded to the values of pre-
hospital PetCO2.
Statistical analysis
Univariate comparison was made with χ2 test for categori-
cal variables and unpaired t test for continuous variables 
with normal distribution (age, pulse rate, PetCO2, NT-proB-
NP, Sao2, modified Boston criteria for HF). The normality of 
distribution was tested with Kolmogorov-Smirnov test. 
Odds ratio (OR) and 95% confidence interval (CI) were cal-
culated to examine risk of acute HF (for adjusted using 
multiple logistic regression).





paroxysmal nocturnal dyspnea 3
dyspnea while walking on level area 2
dyspnea while climbing 1
Physical examination:
heart rate abnormality (1 point if 91-110 beats per minute; 2 points if more than 110 beats per minute) 1 or 2
jugular venous elevation (2 points if greater than 5 cm H2O; 3 points if greater than 5cm H2O plus hepatomegaly or edema) 2 or 3
lung rales (1 point if basilar; 2 points if more than basilar) 1 or 2
wheezing 3
third heart sound 3
hepatojugular reflux 1
additional minor criteria:
ECG changes (HLV, old AMI or non specific ST-T changes, arrhythmia) 1
night cough 1
murmur 1
without sputum and/or fever 1
previous AMI, arrhythmia, or HF 1
HF medications 1
*boston criteria: see reference 13.
†Point value: no more than 4 points are allowed from each of 3 categories; hence the composite score (the sum of the subtotal from each category) 
has a possible maximum of 12 points. the diagnosis of heart failure is classified as “definite” at a score 8 to 12 points, “possible” at a score 5 to 7 
points, and “unlikely” at a score of 4 points or less.
‡abbreviations. aMI – acute myocardial infarction, hlV – hypertrophy of the left ventricle, hF – heart failure.
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The area under the receiver operating characteristic curve 
(AUROC) was used to determine the diagnostic accuracy 
of combination of QC, NT-proBNP, and clinical assessment 
vs NT-proBNP alone or NT-proBNP in combination with 
clinical assessment in differentiating acute HF from COPD/
asthma in pre-hospital emergency setting. We compared 
the areas under different curves using the technique pro-
posed by Hanley and McNeil (20) and Jannuzi (8). Single ar-
eas were calculated and compared with univariate Z score 
testing.
Univariate analysis was performed for all variables pertinent 
to diagnose HF or pulmonary disease, and multivariate 
analysis was performed to simultaneously identify poten-
tial independent predictor variables of a final diagnosis of 
acute HF. Significant variables identified by univariate anal-
ysis with a P value <0.05 were entered into a logistic regres-
sion analysis. This enabled adjusted OR (for confounding) 
to be calculated and identified any factor that affected the 
primary outcome variable (HF). Variables considered in the 
analysis were age, nocturnal dyspnea, orthopnea, cough, 
sputum production, fever, murmur, rales, wheezes, jugular 
venous distension, lower extremity edema, ECG-normal si-
nus rhythm, asthma/COPD medications, HF medications, 
troponin t > 0.03 ng/mL, PetCO2, NT-proBNP, endotracheal 
intubation, previous AMI, HF, or COPD, and modified Bos-
ton criteria for HF.
Sensitivity, specificity, and negative and positive pre-
dictive values were estimated for NT-proBNP and 
table 2. univariate analysis for all demographic and clinical variables pertinent to diagnosis of acute hF or pulmonary disease 
(n = 441)*
Variable† Pulmonary-related dyspnea (n = 203) acute hF-related dyspnea (n = 238) P‡
Age  50.3 ± 14.8   67.9 ± 10.5   0.001
Sex (male/female) (%)  65.3/34.7   58.1/41.9   0.760
Nocturnal dyspnea (Y/N)  13/190  79/159 <0.001
Orthopnea (Y/N)  16/187  91/147 <0.001
Cough (Y/N) 110/93  62/176 <0.001
Sputum production (Y/N)  55/148  15/223 <0.001
Fever (Y/N)  48/155  14/224 <0.001
Murmur (Y/N)  10/193  69/169 <0.001
Rales (Y/N)  24/179 141/97 <0.001
Wheezes (Y/N) 150/53  90/148 <0.001
Pulse rate/min 112.1 ± 18.5  103.5 ± 14.8   0.640
Jugular venous distension (Y/N)   6/197  55/183 <0.001
Lower extremity edema (Y/N)  26/177 114/124 <0.001
ECG-normal sinus rhythm (Y/N) 164/39 101/137 <0.001
Asthma/COPD medications (Y/N) 179/24  43/195 <0.001
HF medications (Y/N)  56/147 162/76 <0.001
Troponin t > 0.03 ng/mL (Y/N)  26/177  86/152 <0.001
PetCO2 (kPa)   6.4 ± 1.1    3.8 ± 1.2   0.006
NT-proBNP (pg/mL) 687.2 ± 479.5 2756.8 ± 885.3   0.004
Sao2 (%)  74.6 ± 9.6   69.8 ± 12.3   0.730
ETI (Y/N)   8/195  21/217   0.026
Previous arrhythmia (Y/N)  14/189  95/143 <0.001
Previous AMI (Y/N)  15/188  80/158 <0.001
Previous CHF (Y/N)  38/165 164/74 <0.001
Previous COPD (Y/N) 159/44  51/187 <0.001
Modified Boston Criteria for diagnosing HF§   5.7 ± 1.9   10.2 ± 1.61 <0.001
*abbreviations: Y – yes, n – no, Petco2 – partial pressure of end-tidal co2, nt-probnP – amino-terminal pro-brain natriuretic peptide, hF – heart 
failure, chF – congestive heart failure, aMI – acute myocardial infarction, Sao2 – arterial oxygen saturation, etI – endotracheal intubation; coPd 
– chronic obstructive pulmonary disease.
†Results are presented as mean ± standard deviation for normally distributed data or ratio or percentage for other variables.
‡univariate comparison was made with χ2 test for categorical variables and t test for continuous variables. For the evaluation of diagnostic accu-
racy, patients were divided into two groups: hF-related acute dyspnea and pulmonary related acute dyspnea (coPd/asthma). 
§boston criteria according to ref. 13.
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PetCO2 for different cut-off points. As established in PRIDE 
study (10), the suggested NT-proBNP concentrations for 
identifying acute HF were greater than 450 pg/mL for pa-
tients younger than 50 years and greater than 900 pg/mL 
for patients aged 50 years or more, whereas 300 pg/mL 
was suggested as an optimal cut-off point for excluding 
HF. The suggested PetCO2 values for identifying acute HF 
were 4 kPa or less, and the cut-off point for excluding HF 
was PetCO2≥8 kPa.
NT-proBNP levels, as well as capnometry, were determined 
in the subgroup of patients with a previous history of pul-
monary disease but finally diagnosed as acute HF, and in 
the subgroup of patients with a history of HF but finally di-
agnosed as acute pulmonary disease (COPD/asthma).
AUROC analysis was performed using Analyze-It software 
(Leeds, UK) whereas other analyses were performed using 
SPSS software (SPSS, Inc., Chicago, IL, USA).
ReSultS
The baseline clinical and demographic characteristics of 
the study population are presented in Table 2. Mean age in 
the group of patients with acute HF was 68.9 ± 10.5 years; 
188 (58%) were men. HF group was significantly older.
diagnostic accuracy of combination of Qc, nt-probnP, 
and clinical assessment in differentiating hF-related 
acute dyspnea from pulmonary-related acute dyspnea
By using of AUROC, the sensitivity and 1- specificity were 
compared for different cut-off points for NT-proBNP alone 
vs combination of NT-proBNP + clinical assessment vs 
combination of NT-proBNP + clinical assessment + Pet-
CO2 (Figure 2). The AUROC from NT-proBNP + PetCO2 + 
clinical assessment (AUROC, 0.97; 95% CI, 0.90-0.99) was 
superior to NT-proBNP + clinical assessment (AUROC, 0.94; 
95% CI, 0.88-0.96; P = 0.006) and NT-proBNP testing alone 
(AUROC, 0.90; 95% CI, 0.85-0.94; P = 0.005). Diagnostic 
modality with the combination of the NT-proBNP + clini-
cal assessment was superior to NT-proBNP testing alone 
(P = 0.010).
Identification of independent predictors for final diag-
nosis of acute dyspnea
For the identification of a final diagnosis of acute HF, we 
examined 23 variables (Table 2) in multivariable logis-
tic regression analysis; 11 variables remained signif-
icant after analysis (Table 3). These included an elevated 
NT-proBNP (as a strongest predictor of acute HF), rales, or-
thopnea, HF medications, troponin T, PetCO2, and previ-
ous HF. Asthma medications, cough, fever, and ECG with 
normal sinus rhythm independently predicted respiratory 
causes of dyspnea.
negative and positive predictive values for nt-probnP 
and Petco2 for different cut-off points
In Table 4 and Table 5, sensitivity, specificity, positive and 
negative predictive value are presented for different cut-
off points for NT-proBNP and PetCO2 for the diagnosis of 
acute HF. The value ≥2000 pg/mL for NT-proBNP and value 
≤4 kPa for PetCO2 are strongly independent predictors for 
acute HF.
Figure 2.
area under receiver-operating curve (auRoc): comparison of nt-prob-
nP versus combination nt-probnP + clinical assessment versus combi-
nation nt-probnP + clinical assessment + Petco2. the auRoc was used 
for discrimination for nt-probnP, Petco2, clinical assessment and com-
bination of all three methods. the areas under the different curves were 
compared with each other using the technique proposed by hanley and 
Mcneil (19) and jannuzi (8). Single areas were calculated and compared 
with univariate Z score testing. the auRoc from nt-probnP + clinical 
assessment + Petco2 was superior to others diagnostic modality (P < 
0.001). Red – nt-probnP 0.90 (95% cI 0.85-0.94), blue – nt-pro-bnP + 
clinical judgement (95% cI 0.88-0.96), green – nt-pro-bnP + clinical 
judgement + petco2  0.97 (95% cI 0.90-0.99).
139Klemen et al: Acute Dyspnea in Pre-hospital Emergency Setting
www.cmj.hr
nt-probnP levels, and capnometry, in subgroup of 
patients with a previous history of hF or of pulmonary 
disease
In the group of acute HF dyspneic patients, we did not 
find any significant difference in the value of NT-proBNP 
between subgroup with previous acute HF and previous 
COPD/asthma, but we found significantly higher PetCO2 in 
the subgroup with previous COPD/asthma. In the group 
of COPD/asthma dyspneic patients, we found significantly 
higher value of NT-proBNP in the subgroup with previous 
HF (Table 6).
We did not observe any adverse events from performing 
the index tests or the reference standard.
dIScuSSIon
To our knowledge, this is the first prospective study specifi-
cally designed to assess the utility of NT-proBNP testing in 
combination with PetCO2 and routine clinical assessment 
for the diagnosis of acute HF in pre-hospital setting. Our 
study showed that the combination of NT-proBNP, clinical 
assessment, and capnometry proved to be useful in dif-
ferentiating HF from pulmonary causes of acute dyspnea 
and had a significantly better AUROC for the diagnostic ac-
curacy than each method alone or a combination of two 
of them.
Timely differentiation of HF from other causes of respira-
tory distress may permit the early institution of appropriate 
medical therapy. The symptoms and signs of COPD/asth-
ma exacerbation may frequently be difficult to differenti-
ate from those of acute HF and when the two diagnoses 
coexist, treatment decisions become incrementally more 
complex (21-23).
Routine BNP testing of dyspneic patients in emergency de-
partment has been demonstrated to be a useful method 
for diagnosing and excluding acute HF (7-10). The intro-
duction of BNP measurement in patients with uncertain 
diagnosis may reduce the error rate by over 50% (19).
Measurement of the PetCO2 in the field has already 
become a standard procedure to ensure proper 
table 3. Multiple logistic regression analysis of factors used 
for differentiating between patients with hF-related acute 
dyspnea and pulmonary-related acute dyspnea in prehospital 
emergency setting
Factor* oR (95% cI)† P‡
NT-proBNP 13.6 (7.2-25.7) <0.001
Rales   5.8 (1.9-12.4)   0.010
Orthopnea   7.5 (2.2-19.8) <0.001
HF medications   2.8 (1.5-4.8)   0.008
Troponin T   1.9 (1.1-3.9)   0.020
PetCO2   6.9 (2.4-17.5) <0.001
Previous HF   6.8 (2.2 -19.7) <0.001
Asthma/COPD medications   0.14 (0.04-0.53)   0.030
Cough   0.32 (0.18-0.79)   0.039
ECG – normal sinus rhythm   0.44 (0.24-0.85)   0.038
Fever   0.19 (0.06-0.58)   0.018
*abbreviations: nt-probnP – amino-terminal pro-brain natriuretic 
peptide, Petco2 – partial pressure of end-tidal co2, hF – heart failure; 
coPd – chronic obstructive pulmonary disease; oR – odds ratio; cI 
– confidence interval.
†univariable screening was performed on clinical, historical, ecG 
and biochemical variables to identify potential predictors of acute 
hF. odds ratios for the presence of acute hF were generated and 
expressed with 95% cI.
‡Multivariable analysis with logistic regression was used to identify 
potential predictor variables of a final diagnosis of acute hF (variables 
from univariate analysis with P < 0.05 for entry into model).
table 4. test characteristics of nt-probnP for the diagnosis of 
acute hF for different cut-off points*










300 99 (92-100) 54 (45-65) 98 (91-100) 51 (42-62)
700 98 (90-100) 65 (55-72) 97 (89-100) 59 (50-68)
1000 90 (82-97) 76 (68-83) 92 (80-99) 68 (62-77)
2000 84 (77-94) 83 (72-90) 88 (78-94) 76 (69-85)
3000 67 (55-80) 95 (88-99) 71 (64-80) 93 (84-99)
*abbreviations: nt-probnP – amino-terminal pro-brain natriuretic 
peptide; cI – confidence interval.
table 5. test characteristics of Petco2 for the diagnosis of 
acute heart failure for different cut-off point*
















9.3 97 (92-100) 33 (27-40) 98 (92-100) 30 (25-37)
8.0 94 (88-98) 41 (35-47) 92 (87-99) 35 (31-39)
6.7 90 (80-97) 62 (55-70) 91 (86-94) 42 (36-48)
5.3 82 (76-89) 76 (70-79) 86 (80-91) 63 (58-69)
4.7 76 (71-83) 85 (79-91) 78 (72-83) 68 (63-75)
4.0 68 (60-76) 91 (86-96) 69 (63-72) 76 (70-82)
3.3 61 (55-69) 96 (90-99) 60 (52-66) 83 (76-90)
*abbreviations: Petco2 – partial pressure of end-tidal co2.
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placement and function of the endotracheal tube and to 
monitor the adequacy of ventilation (24,25). Some previ-
ous studies have also suggested that QC may be useful in 
differentiating between cardiac and obstructive causes of 
respiratory distress (11,12).
PetCO2 is reported to have a prognostic value in patients 
with HF at rest and during exercise testing (26,27). Matsu-
mato et al (28) found that PetCO2 could become a new 
ventilatory abnormality marker for impaired cardiac out-
put response. Brown et al (11) found that PetCO2 levels for 
pulmonary edema/CHF patients differed significantly from 
those of asthma/COPD patients. We also found a signifi-
cant difference in PetCO2 values between HF and COPD/
asthma, and concluded that capnometry could represent 
an objective additional method for differentiating acute 
dyspnea in pre-hospital setting. With adding the PetCO2 in 
our study, we improved the sensitivity and specificity in dif-
ferentiating the cause of acute dyspnea (especially in COPD 
patients with severe exacerbation and coexisting HF).
Combination of NT-proBNP and PetCO2 presents two dif-
ferent ways and mechanisms of verification of HF. It intro-
duces an opportunity for integration of biochemical and 
pathophysiologic measurement in a new complementary 
method. Both devices are accessible in the field and pres-
ent an effective way in differentiating respiratory distress 
in prehospital setting. Our study confirmed that the com-
bination of these two parameters had a strong diagnostic 
value.
We also found an association between the history of pre-
vious COPD/asthma or HF and the current values of NT-
proBNP and PetCO2. Our results showed that higher values 
of NT-proBNP in acute dyspneic patients due to COPD/
asthma correlated with a history of HF, and higher values 
of PetCO2 in acute dyspneic patients due to HF correlated 
with a history of COPD/asthma. Similarly, Morrison et al 
(23) reported significantly higher BNP levels in patients 
with HF than in patients with pulmonary disease. Pa-
tients with history of HF but with current COPD diagnosis 
had higher BNP levels than patients without history of HF.
Tung et al (29) found that in patients without previous HF, 
median NT-proBNP levels were higher than in patients 
with new-onset HF than in those with COPD/asthma ex-
acerbation. High clinical suspicion for acute HF detected 
only 23% of patients with new-onset HF, whereas 82% of 
these patients had elevated NT-proBNP levels. In patients 
who had both previous acute HF and COPD/asthma, medi-
an NT-proBNP levels were significantly higher in those with 
acute HF than in those with COPD/asthma exacerbation. 
McCullough et al (30) investigated whether BNP could dis-
tinguish new-onset HF in patients with a history of COPD/
asthma presenting with dyspnea to the emergency de-
partment and concluded that the yield of adding routine 
BNP testing in these cases was approximately 20%.
The prehospital emergency physicians offer the earliest 
treatment of acute dyspnea, performed as close as clinical-
ly possible to the event. Based on clinical judgment alone, 
it is sometimes very difficult to distinguish cardiac from re-
spiratory causes of dyspnea. In fact, even in experienced 
centers, diagnostic accuracy is lower than 80% (19). If the 
prehospital physicians have the values of NT-proBNP and 
PetCO2 at their disposal, the diagnostic dilemmas in differ-
entiating causes of respiratory distress are reduced and the 
treatment possibilities in clinical obscure cases are mainly 
improved. This is particularly important for more complex 
treatment (eg, diuretics, morphine, vasodilatators, or ino-
tropes).
This study has some limitations: 1) prehospital emergency 
physicians were not blinded to the values of PetCO2 be-
cause capnometry represents the routine prehospital test. 
In our opinion, this fact did not induce bias because the 
physicians were unaware of the differential diagnostic im-
portance of PetCO2 for the purpose of the study (in the dif-
ferentiation of cardiac and pulmonary causes of shortness 
of breath – blindness for the purpose of the study); 2) in the 
table 6. Subgroup analysis of amino-terminal pro-brain natriuretic peptide (nt-probnP) and partial pressure of end-tidal co2 
(Petco2) values in a group of acute heart failure (hF)-related dyspnea (n = 238) and pulmonary related dyspnea (n = 203)
Patients with
acute hF*-related dyspnea pulmonary related dyspnea
previous history of 
hF (n = 164)




previous history of 
hF (n = 38)




NT-proBNP (pg/mL) 2885.6 ± 944.4 2395.4 ± 864.4 0.368 1453.3 ± 552.3 741.5 ± 435.5 0.010
PetCO2 (kPa)    3.8 ± 1.2    5.8 ± 1.3 0.009    5.1 ± 1.2    6.2 ± 1.5 0.297
*abbreviations: hF – heart failure; coPd – chronic obstructive pulmonary disease.
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majority of patients, spirometry or simple forced expirato-
ry volume in one second (FEV1) were not measured and 
evaluated, thus the severity of COPD/asthma is not differ-
entiated in the study; and 3) severe additional factors may 
have an impact of the reliability of PetCO2 (some patients 
in the study hyperventilated, had periodic breathing, were 
intubated, or had ventilation/perfusion mismatch) (31).
In conclusion, NT-proBNP in combination with capnom-
etry and clinical assessment was superior to NT-proBNP 
alone or NT-proBNP in combination with clinical assess-
ment in differentiating between cardiac and respiratory 
causes of acute dyspnea in prehospital emergency setting. 
QC and NT-proBNP measurement can improve the differ-
entiation and treatment of acute dyspnea in the first hours 
of its appearance. Wider use of these routine procedures 
can be helpful for emergency physicians in everyday work, 
but further investigation (eg, a larger multicentric study) is 
needed to confirm the utility of these methods in the pre-
hospital setting.
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